Solid Biosciences (SLDB) Equity Ratio (2017 - 2024)
Historic Equity Ratio for Solid Biosciences (SLDB) over the last 8 years, with Q3 2024 value amounting to 0.79.
- Solid Biosciences' Equity Ratio rose 89.68% to 0.79 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.79, marking a year-over-year increase of 89.68%. This contributed to the annual value of 0.77 for FY2023, which is 571.45% down from last year.
- As of Q3 2024, Solid Biosciences' Equity Ratio stood at 0.79, which was up 89.68% from 0.84 recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Equity Ratio ranged from a high of 0.9 in Q3 2021 and a low of 0.55 during Q3 2020
- In the last 5 years, Solid Biosciences' Equity Ratio had a median value of 0.8 in 2023 and averaged 0.8.
- Its Equity Ratio has fluctuated over the past 5 years, first crashed by 3380.78% in 2020, then surged by 6350.28% in 2021.
- Solid Biosciences' Equity Ratio (Quarter) stood at 0.77 in 2020, then grew by 16.11% to 0.9 in 2021, then decreased by 9.23% to 0.81 in 2022, then dropped by 5.71% to 0.77 in 2023, then rose by 2.82% to 0.79 in 2024.
- Its Equity Ratio was 0.79 in Q3 2024, compared to 0.84 in Q2 2024 and 0.85 in Q1 2024.